Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ras in digestive oncology: from molecular biology to clinical implications.

Current opinion in oncology - 1 Jul 2014

Charette Nicolas, Vandeputte Caroline, Stärkel Peter

Abstract excerpt

PURPOSE OF REVIEW: The modalities of Ras mutation detection, its role as a predictive biomarker, mechanisms of wild-type Ras activation, and the role of Ras-directed targeted therapies will be discussed mainly in colorectal cancer. RECENT FINDINGS: RAS genotype is generally considered to be highly concordant between primary colorectal tumours and metastases. However, recent data show significant discordance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genes, ras

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-raf

Share to ras Proteins

Source

Identifiers

PMID: 24849046
DOI: 10.1097/CCO.0000000000000088

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ras in digestive oncology: from molecular biology to clinical implications.PMID 24849046Read ↗

RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implicationsSemantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.Semantic proximity Read ↗

RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.Semantic proximity Read ↗

Gastrointestinal cancer: is now the time to extend biomarker stratification to other RAS-family genes?Semantic proximity Read ↗

Clinical and prognostic implications of RAS mutations in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF: drug targets and predictive biomarkers.Semantic proximity Read ↗

Targeting BRAF and RAS in Colorectal CancerSemantic proximity Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.